New York State Common Retirement Fund Biotechnology

New York State Common Retirement Fund

$74.6 Billion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
VRTX Vertex Pharmaceuticals Inc	$124B	$146 Million 0.2% of portfolio	362,334	Q4 2024 Added 0.79%
REGN Regeneron Pharmaceuticals, Inc.	$75.1B	$97.9 Million 0.13% of portfolio	137,386	Q3 2024 Reduced 6.51%
VCEL Vericel Corp	$2.45B	$46.9 Million 0.06% of portfolio	854,902	Q4 2024 Reduced 0.9%
TECH Bio Techne Corp	$2.55B	$39.2 Million 0.05% of portfolio	544,058	Q4 2024 Added 4.24%
ARGX Argenx Se	$35.7B	$39.1 Million 0.05% of portfolio	63,534	Q4 2024 Reduced 39.22%
VCYT Veracyte, Inc.	$2.8B	$31.1 Million 0.04% of portfolio	785,971	Q4 2024 Added 0.4%
ASND Ascendis Pharma A/S	$8.51B	$28.2 Million 0.04% of portfolio	204,482	Q4 2024 Added 14.03%
INSM Insmed Inc	$11B	$21.9 Million 0.03% of portfolio	317,753	Q4 2024 Added 8.53%
HALO Halozyme Therapeutics, Inc.	$8.04B	$17.6 Million 0.02% of portfolio	368,010	Q4 2024 Reduced 52.18%
ALNY Alnylam Pharmaceuticals, Inc.	$30.8B	$17 Million 0.02% of portfolio	72,228	Q4 2024 Reduced 5.25%
MRNA Moderna, Inc.	$13.9B	$16.6 Million 0.02% of portfolio	398,132	Q4 2024 Reduced 0.65%
SRPT Sarepta Therapeutics, Inc.	$9.31B	$16.2 Million 0.02% of portfolio	133,362	Q4 2024 Reduced 2.2%
BNTX Bio N Tech Se	$29.1B	$14.3 Million 0.02% of portfolio	125,296	Q4 2024 Reduced 42.54%
SWTX Spring Works Therapeutics, Inc.	$3.63B	$13.2 Million 0.02% of portfolio	364,060	Q3 2024 Added 1.88%
MDGL Madrigal Pharmaceuticals, Inc.	$5.75B	$12.6 Million 0.02% of portfolio	40,815	Q4 2024 Reduced 12.12%
UTHR United Therapeutics Corp	$16.4B	$12.3 Million 0.02% of portfolio	34,815	Q4 2024 Reduced 5.43%
NVO Novo Nordisk A S	$199B	$11.3 Million 0.02% of portfolio	131,236	Q4 2024 Added 66.82%
LGND Ligand Pharmaceuticals Inc	$2.04B	$9.9 Million 0.01% of portfolio	92,418	Q4 2024 Added 7.1%
MIRM Mirum Pharmaceuticals, Inc.	$1.93B	$9.44 Million 0.01% of portfolio	228,351	Q3 2024 Added 20.11%
TGTX Tg Therapeutics, Inc.	$4.49B	$9.01 Million 0.01% of portfolio	299,396	Q4 2024 Added 403.06%
FOLD Amicus Therapeutics, Inc.	$2.58B	$8.88 Million 0.01% of portfolio	943,114	Q4 2024 Added 2.79%
IDYA Ideaya Biosciences, Inc.	$1.05B	$8.51 Million 0.01% of portfolio	331,072	Q3 2024 Reduced 14.57%
IOVA Iovance Biotherapeutics, Inc.	$912M	$8.3 Million 0.01% of portfolio	1,121,417	Q4 2024 Reduced 8.1%
CRNX Crinetics Pharmaceuticals, Inc.	$2.01B	$7.95 Million 0.01% of portfolio	155,426	Q4 2024 Added 5.24%
RPRX Royalty Pharma PLC	$14.6B	$6.81 Million 0.01% of portfolio	266,815	Q4 2024 Reduced 4.82%
JAZZ Jazz Pharmaceuticals PLC	$8.53B	$6.68 Million 0.01% of portfolio	54,273	Q4 2024 Reduced 5.0%
BMRN Biomarin Pharmaceutical Inc	$12.7B	$6.16 Million 0.01% of portfolio	93,645	Q4 2024 Reduced 4.68%
IMCR Immunocore Holdings PLC	$1.31B	$5.98 Million 0.01% of portfolio	202,806	Q3 2024 Reduced 12.81%
INCY Incyte Corp	$16B	$5.57 Million 0.01% of portfolio	80,641	Q4 2024 Reduced 6.38%
RNA Avidity Biosciences, Inc.	$1.62B	$5.37 Million 0.01% of portfolio	184,811	Q4 2024 Added 0.32%
EXEL Exelixis, Inc.	$11.9B	$5.24 Million 0.01% of portfolio	157,257	Q4 2024 Reduced 10.51%
XENE Xenon Pharmaceuticals Inc.	$2.47B	$5.2 Million 0.01% of portfolio	132,521	Q3 2024 Reduced 12.14%
VKTX Viking Therapeutics, Inc.	$2.61B	$4.78 Million 0.01% of portfolio	118,898	Q4 2024 Reduced 2.86%
CDMO Avid Bioservices, Inc.	$776M	$4.29 Million 0.01% of portfolio	347,665	Q4 2024 Reduced 64.74%
ADMA Adma Biologics, Inc.	$3.11B	$4.19 Million 0.01% of portfolio	244,019	Q4 2024 Reduced 4.52%
PCVX Vaxcyte, Inc.	$4.73B	$3.87 Million 0.01% of portfolio	47,295	Q4 2024 Reduced 17.58%
KRYS Krystal Biotech, Inc.	$4.82B	$3.66 Million 0.0% of portfolio	23,382	Q4 2024 Reduced 9.59%
DNLI Denali Therapeutics Inc.	$2.78B	$2.95 Million 0.0% of portfolio	144,724	Q4 2024 Reduced 3.46%
IONS Ionis Pharmaceuticals Inc	$4.59B	$2.95 Million 0.0% of portfolio	84,261	Q4 2024 Reduced 57.61%
RVMD Revolution Medicines, Inc.	$3.63B	$2.78 Million 0.0% of portfolio	63,601	Q4 2024 Added 12.85%
ROIV Roivant Sciences Ltd.	$7.52B	$2.6 Million 0.0% of portfolio	219,793	Q4 2024 Added 15.2%
RARE Ultragenyx Pharmaceutical Inc.	$2.98B	$2.46 Million 0.0% of portfolio	58,571	Q4 2024 Reduced 7.87%
TARS Tarsus Pharmaceuticals, Inc.	$1.28B	$2.38 Million 0.0% of portfolio	43,004	Q4 2024 Reduced 3.59%
BGNE Bei Gene, Ltd.	$23.5B	$2.25 Million 0.0% of portfolio	12,173	Q4 2024 Added 42.06%
INVA Innoviva, Inc.	$1.26B	$2.18 Million 0.0% of portfolio	125,892	Q3 2024 Reduced 16.57%
HRMY Harmony Biosciences Holdings, Inc.	$2.04B	$2.13 Million 0.0% of portfolio	61,878	Q4 2024 Added 30.35%
HRTX Heron Therapeutics, Inc.	$205M	$2.02 Million 0.0% of portfolio	1,321,006	Q4 2024 Added 3.21%
CORT Corcept Therapeutics Inc	$6.81B	$1.99 Million 0.0% of portfolio	39,425	Q3 2024 Reduced 16.16%
LEGN Legend Biotech Corp	$6.65B	$1.93 Million 0.0% of portfolio	59,276	Q4 2024 Added 196.08%
EWTX Edgewise Therapeutics, Inc.	$1.71B	$1.91 Million 0.0% of portfolio	71,366	Q4 2024 Added 6.39%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.